# A Study of Intravenous Formulation of Guselkumab Using Prefilled Syringes and Final Vialed Product in Healthy Participants

> **NCT04617691** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 140 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Guselkumab

## Key facts

- **NCT ID:** NCT04617691
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-30
- **Primary completion:** 2021-07-20
- **Final completion:** 2021-07-20
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2021-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04617691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04617691, "A Study of Intravenous Formulation of Guselkumab Using Prefilled Syringes and Final Vialed Product in Healthy Participants". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04617691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*